Q-omics provides the consensus-scored MCRIP2 profile across patient tissues and cancer cell-line models. MCRIP2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MCRIP2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MCRIP2 RNA expression shows 18,686 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where MCRIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCRIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCRIP2 survival associations across molecular data types. MCRIP2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCRIP2 RNA expression–survival associations across cancer types. High MCRIP2 expression shows unfavorable associations in UCS, but favorable associations in MESO, BLCA, HNSC, LUSC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MCRIP2 RNA expression.
This table summarizes MCRIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MCRIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCRIP2 shows lower tumor expression in THCA and higher tumor expression in LUAD, STAD, UCEC, BRCA and LIHC. The THCA box plot shows higher MCRIP2 RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p < 0.001).
This table shows molecular features associated with MCRIP2 in patient tissues and cancer cell lines. In patient samples, MCRIP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MCRIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
